Company intelligence / Profile preview
Sea Pharmaceuticals
Cambridge, Massachusetts, United Statesseapharmaceuticals.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sea Pharmaceuticals is developing proprietary synthetic small molecules targeting central nervous system disorders, specifically tinnitus, epilepsy, and sporadic ALS. The company’s lead programs are in the discovery and preclinical stages with a focus on novel oral neurotherapeutics. No published clinical results or late-stage trial data are available as of June 2025.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Sea Pharmaceuticals collaborates with contract science labs for chemistry/neurobiology/pharmacology and works with business service firms for law, securities, insurance, accounting. No major pharma partnerships disclosed.
Beyond the preview
Go deeper on Sea Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sea Pharmaceuticals.